Epigenetic Cancer Therapy
Edited By: Steven Gray, Senior Clinical Scientist & Adjunct Assistant Professor at the Thoracic Oncology Research Group, Trinity Centre for Health Sciences, St. James's Hospital, Dublin, Ireland
Description Epigenetic Cancer Therapy unites issues central to a translational audience actively seeking to understand the topic. It is ideal for cancer specialists, including oncologists and clinicians, but also provides valuable information for researchers, academics, students, governments, and decision-makers in the healthcare sector.
The text covers the basic background of the epigenome, aberrant epigenetics, and its potential as a target for cancer therapy, and includes individual chapters on the state of epigenome knowledge in specific cancers (including lung, breast, prostate, liver).
The book encompasses both large-scale intergovernmental initiatives as well as recent findings across cancer stem cells, rational drug design, clinical trials, and chemopreventative strategies. As a whole, the work articulates and raises the profile of epigenetics as a therapeutic option in the future management of cancer.
Key Features
- Concisely summarizes the therapeutic implications of recent, large-scale epigenome studies, including the cancer epigenome atlas
- Discusses targeted isoform specific versus pan-specific inhibitors, a rational drug design approach to epigenetics relevant to pharmacoepigenetic clinical applications
- Covers new findings in the interplay between cancer stem cells (CSCs) and drug resistance, demonstrating that epigenetic machinery is a candidate target for the eradication of these CSCs
Readership
Researchers in molecular biology, genetics, and clinical therapy who are interested in the role of epigenetics in cancer biology or those seeking novel means to treat cancer.
Table of Contents
- Introduction
- DNA Methylation & Hydroxymethylation in Cancer
- Writers, Readers, and Erasers of Epigenetic Marks
- MicroRNAs and Cancer
- Long Noncoding RNAs (lncRNAs) and Cancer
- Ribosomal RNA Methylation and Cancer
- Mining the Epigenetic Landscape: Surface Mining or Deep Underground
- Development of Epigenetic Targeted Therapies in Hematological Malignancies: From Serendipity to Synthetic Lethality
- Epigenetic Therapy in Lung Cancer and Mesothelioma
- Breast Cancer Epigenetics
- Therapeutic Applications of the Prostate Cancer Epigenome
- Liver Cancer (Hepatocellular Carcinoma)
- Neuroblastoma
- The Epigenetics of Medulloblastoma
- Clinical Significance of Epigenetic Alterations in Glioblastoma
- Esophageal Cancer
- Nasopharyngeal Cancer
- Nutritional Epigenetic Inhibitors in the Field of Cancer: New Avenues for Chemopreventive Approaches
- Emerging Epigenetic Therapies - Lysine Methyltransferase/PRC Complex Inhibitors
- Inhibitors of Jumonji C Domain Histone Demethylases
- Emerging Epigenetic Therapies - Lysine Acetyltransferase Inhibitors
- Emerging Epigenetic Therapies - Bromodomain Ligands
- Clinical Trials
- Genetic Intratumor Heterogeneity
- Epigenetics Underpinning DNA Damage repair
- Epigenetics of Cisplatin Resistance
- Therapeutically Targeting Epigenetic Regulation of Cancer Stem Cells
- Personalized Therapy - Chemosensitivity Testing
- Personalized Therapy - Epigenetic Profiling as Predictors of Prognosis and Response
Available now at Store.Elsevier.com